GETIBN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationRobust operating and free cash flow supports internal investment, debt service and shareholder returns. The high conversion of earnings into cash also indicates that reported profitability is generally backed by tangible cash generation.
Recurring Installed-Base RevenueAftermarket services, consumables and maintenance create recurring revenue alongside capital-equipment sales. This installed-base model can improve revenue visibility and customer retention across hospital and life-science markets.
Profitability RecoveryThe rebound in EBIT and net margins shows that profitability is recovering from recent weakness. If sustained, improved earnings quality can strengthen cash generation and provide greater financial capacity for operations and investment.
Bears Say
Weak Reported Revenue GrowthThe reported revenue-growth measure is negative, indicating that top-line expansion is not consistently established. Prolonged weak growth could limit operating leverage and make future profit improvement more dependent on cost control.
Margins Below Historical LevelsAlthough profitability has improved, margins remain below earlier peaks, pointing to persistent pressure from product mix, costs or pricing. This reduces confidence that the current recovery represents a fully restored earnings structure.
Higher Leverage And Uneven Cash FlowRising leverage reduces financial flexibility compared with prior years, while uneven historical free cash flow makes cash planning less predictable. Together, these factors could constrain investment or shareholder returns if operating performance weakens.
GETIBN FAQ
What was Getinge AB (UK)’s price range in the past 12 months?
Currently, no data Available
What is Getinge AB (UK)’s market cap?
Getinge AB (UK)’s market cap is $112.40B.
When is Getinge AB (UK)’s upcoming earnings report date?
Getinge AB (UK)’s upcoming earnings report date is Oct 20, 2026 which is in 37 days.
How were Getinge AB (UK)’s earnings last quarter?
Getinge AB (UK) released its earnings results on Jul 17, 2026. The company reported $6.331 earnings per share for the quarter, beating the consensus estimate of $3.832 by $2.499.
Is Getinge AB (UK) overvalued?
According to Wall Street analysts Getinge AB (UK)’s price is currently Undervalued.
Does Getinge AB (UK) pay dividends?
Getinge AB (UK) does not currently pay dividends.
What is Getinge AB (UK)’s EPS estimate?
Getinge AB (UK)’s EPS estimate is 4.43.
How many shares outstanding does Getinge AB (UK) have?
Getinge AB (UK) has 254,152,370 shares outstanding.
What happened to Getinge AB (UK)’s price movement after its last earnings report?
Getinge AB (UK) reported an EPS of $6.331 in its last earnings report, beating expectations of $3.832. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Getinge AB (UK)?
Currently, no hedge funds are holding shares in MX:GETIBN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Getinge AB (UK)
Getinge AB, founded in 1904 and headquartered in Gothenburg, Sweden, is a prominent global supplier of medical technology solutions. The company's extensive portfolio is designed for critical healthcare environments, including operating rooms, intensive care units, and sterile processing facilities. Its operations are divided into three core segments: Acute Care Therapies, Life Science, and Surgical Workflows. Getinge offers a comprehensive array of specialized equipment and systems. This encompasses advanced solutions for sterile processing and containment, such as sterilizers, washers, isolators, and automated logistic systems. For the life sciences sector, they provide bioreactors, bioprocess control systems, and associated analytics tools. Within acute care and surgical settings, their offerings range from anesthesia machines, specialized monitoring systems, and various disposables, to instruments for cardiac surgery (like beating heart stabilizers), mechanical ventilation products, and extracorporeal life support (ECMO) solutions. Additionally, Getinge provides infrastructure for operating rooms, including lighting, tables, modular systems, and integrated management tools, alongside products for cleaning, disinfection, packaging, and comprehensive sterile supply management. Their product line further extends to diverse catheters (thoracic, endovascular), endoscopic vessel harvesting systems, patient flow and transport solutions, and specialized devices for vascular and cardiothoracic surgery. The company distributes its broad range of products globally through its proprietary sales companies, as well as via agents and distributors, serving markets across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region.
GETIBN Stock 12 Month Forecast
Average Price Target
$449.68
BONESUPPORT HOLDING AB
―
Xvivo Perfusion AB
―
Bactiguard Holding AB
―
Sectra AB Class B
―
Sedana Medical AB
―